With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...